NCI-Sponsored trial for the evaluation of safety and preliminary efficacy of 3′-Deoxy-3′-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: Preliminary efficacy studies

Alexander M. Spence, Mark Muzi, Jeanne M. Link, Finbarr O'Sullivan, Janet F. Eary, John M. Hoffman, Lalitha K. Shankar, Kenneth A. Krohn

Research output: Contribution to journalArticlepeer-review

50 Scopus citations

Abstract

Purpose: 3′-Deoxy-3′-[18F]fluorothymidine ([18F]FLT) is being developed for imaging cellular proliferation. The goals were to explore the capacity of FLT-positron emission tomography (PET) to distinguish between recurrence and radionecrosis in gliomas and compare the results to those obtained with 2-fluoro-2-deoxy-d-glucose (FDG). Procedures: Fifteen patients with tumor recurrence and four with radionecrosis, determined by clinical course and magnetic resonance imaging results, were studied by dynamic [18F]FLT-PET with arterial blood sampling. A two-tissue compartment four-rate constant model was used to determine metabolic flux (KFLT), blood to tissue transport (K1), and phosphorylation (k3). FDG-PET scans were obtained 75-90 min postinjection. Results: KFLT and k3, but not K1 or k3/k2+k3, reached significance for separating the recurrence from radionecrosis groups. Standardized uptake value and visual analyses of FLT or FDG images did not reach significance. Conclusions: KFLT (flux) appears to distinguish recurrence from radionecrosis better than other parameters, FLT and FDG semiquantitative approaches, or visual analysis of images of either tracer.

Original languageEnglish (US)
Pages (from-to)343-355
Number of pages13
JournalMolecular Imaging and Biology
Volume11
Issue number5
DOIs
StatePublished - 2009
Externally publishedYes

Keywords

  • 3′-[F]fluoro-3′-deoxythymidine
  • FLT
  • Fluorothymidine
  • Glioma
  • Positron emission tomography (PET)
  • Proliferation imaging
  • Radionecrosis

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'NCI-Sponsored trial for the evaluation of safety and preliminary efficacy of 3′-Deoxy-3′-[<sup>18</sup>F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: Preliminary efficacy studies'. Together they form a unique fingerprint.

Cite this